Intestinal sugar uptake reduction via gut sugar sensor blockade

Overview

This innovative technology targets the reduction of sugar uptake in the intestine by blocking the gut's sugar sensor, identified as the beta2 adrenergic receptor (β2AR). By inhibiting this receptor, which regulates the SGLT1 transporter responsible for sugar absorption, the solution prevents increased sugar uptake. This results in more sugar passing through the gut, reducing calorie intake and aiding weight loss. Additionally, it lowers blood glucose peaks, offering a potential therapeutic approach for managing type 2 diabetes.

Technical specifications

• The primary target is the β2 adrenergic receptor (β2AR), a known GPCR in absorptive gut cells.
• The solution involves a selective compound that blocks β2AR without systemic absorption, minimizing side effects.
• Initial validation showed reduced blood sugar levels in normal rats.

Technology readiness level

The technology is currently at TRL 4, having been validated in normal rat models. Future steps include expanding the research to obesity and type 2 diabetes rodent models to assess efficacy and safety further.